Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Fundamental Analysis

NASDAQ:RCKT - US77313F1066 - Common Stock

3.73 USD
-0.02 (-0.53%)
Last: 8/21/2025, 8:00:02 PM
3.72 USD
-0.01 (-0.27%)
Pre-Market: 8/22/2025, 8:23:50 AM
Fundamental Rating

2

Taking everything into account, RCKT scores 2 out of 10 in our fundamental rating. RCKT was compared to 549 industry peers in the Biotechnology industry. RCKT may be in some trouble as it scores bad on both profitability and health. RCKT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RCKT had negative earnings in the past year.
In the past year RCKT has reported a negative cash flow from operations.
RCKT had negative earnings in each of the past 5 years.
RCKT had a negative operating cash flow in each of the past 5 years.
RCKT Yearly Net Income VS EBIT VS OCF VS FCFRCKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of RCKT (-54.77%) is comparable to the rest of the industry.
The Return On Equity of RCKT (-62.61%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -54.77%
ROE -62.61%
ROIC N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
RCKT Yearly ROA, ROE, ROICRCKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCKT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCKT Yearly Profit, Operating, Gross MarginsRCKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

RCKT has more shares outstanding than it did 1 year ago.
RCKT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RCKT has a worse debt to assets ratio.
RCKT Yearly Shares OutstandingRCKT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RCKT Yearly Total Debt VS Total AssetsRCKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

RCKT has an Altman-Z score of -0.87. This is a bad value and indicates that RCKT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.87, RCKT is in line with its industry, outperforming 59.56% of the companies in the same industry.
RCKT has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of RCKT (0.05) is worse than 61.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -0.87
ROIC/WACCN/A
WACCN/A
RCKT Yearly LT Debt VS Equity VS FCFRCKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

RCKT has a Current Ratio of 9.19. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.19, RCKT is doing good in the industry, outperforming 77.41% of the companies in the same industry.
A Quick Ratio of 9.19 indicates that RCKT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.19, RCKT is doing good in the industry, outperforming 77.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.19
Quick Ratio 9.19
RCKT Yearly Current Assets VS Current LiabilitesRCKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.11% over the past year.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RCKT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.89% on average per year.
RCKT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 471.62% yearly.
EPS Next Y17.1%
EPS Next 2Y15.6%
EPS Next 3Y16.34%
EPS Next 5Y11.89%
Revenue Next Year41559.1%
Revenue Next 2Y5267.1%
Revenue Next 3Y1339.88%
Revenue Next 5Y471.62%

3.3 Evolution

RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RCKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCKT Price Earnings VS Forward Price EarningsRCKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCKT Per share dataRCKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

RCKT's earnings are expected to grow with 16.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.6%
EPS Next 3Y16.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCKT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (8/21/2025, 8:00:02 PM)

Premarket: 3.72 -0.01 (-0.27%)

3.73

-0.02 (-0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners90.25%
Inst Owner Change-13.12%
Ins Owners2.86%
Ins Owner Change14.33%
Market Cap401.87M
Analysts74.17
Price Target8.63 (131.37%)
Short Float %10.86%
Short Ratio3.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.95%
Min EPS beat(2)10.56%
Max EPS beat(2)15.34%
EPS beat(4)3
Avg EPS beat(4)8.29%
Min EPS beat(4)-1.16%
Max EPS beat(4)15.34%
EPS beat(8)6
Avg EPS beat(8)8.19%
EPS beat(12)7
Avg EPS beat(12)3.49%
EPS beat(16)10
Avg EPS beat(16)3.12%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34.35%
PT rev (3m)-77.88%
EPS NQ rev (1m)0.48%
EPS NQ rev (3m)5.28%
EPS NY rev (1m)0%
EPS NY rev (3m)4.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-8.43%
Revenue NY rev (3m)-63.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.98
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.94
OCFYN/A
SpS0
BVpS3.83
TBVpS3.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.77%
ROE -62.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.19
Quick Ratio 9.19
Altman-Z -0.87
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)144.02%
Cap/Depr(5y)620.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.27%
EPS Next Y17.1%
EPS Next 2Y15.6%
EPS Next 3Y16.34%
EPS Next 5Y11.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year41559.1%
Revenue Next 2Y5267.1%
Revenue Next 3Y1339.88%
Revenue Next 5Y471.62%
EBIT growth 1Y-2.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.49%
EBIT Next 3Y8.53%
EBIT Next 5YN/A
FCF growth 1Y-3.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.2%
OCF growth 3YN/A
OCF growth 5YN/A